Premium
Sustained improvement in health‐related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti‐tumor necrosis factor therapy
Author(s) -
Sherman Michael,
Tsynman Donald N,
Kim Albert,
Arora Jyoti,
Pietras Timothy,
Messing Susan,
St Hilaire Lydia,
Yoon Sonia,
Decross Arthur,
Shah Ashok,
Saubermann Lawrence
Publication year - 2014
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12125
Subject(s) - medicine , depression (economics) , quality of life (healthcare) , visual analogue scale , inflammatory bowel disease , disease , crohn's disease , tumor necrosis factor alpha , rating scale , physical therapy , psychology , developmental psychology , nursing , economics , macroeconomics
Objective The aim of this study was to determine whether the effects of prolonged therapy (≥1 year) with anti‐tumor necrosis factor ( TNF ) agents were sustained on the health‐related quality of life ( HRQoL ) in patients with inflammatory bowel disease ( IBD ). Methods A cross‐sectional survey of patients with IBD who were treated with anti‐ TNF agents was performed. Results of the validated HRQoL measures (inflammatory bowel disease questionnaire [ IBDQ ], E uro Q o L ‐5 dimensions [ EQ ‐5 D ], health status visual analogue scale [ VAS ] and the Zung self‐rating depression scale) were recorded and compared between patients treated with anti‐ TNF agents for <1 year and ≥1 year. Results A total of 41 patients were finally enrolled in the study. Among them, 11 (26.8%) had received anti‐ TNF therapy for less than one year with a median duration of 7 months (range 3–11 months), while the other 30 (73.2%) had been treated for ≥1 year with a median duration of 42 months (range 12–104 months). C rohn's disease was the most common type in both groups. None of the mean IBDQ , EQ ‐5 D and EQ ‐5 D plus VAS, or Z ung self‐rating depression scale scores differed significantly between the two groups of patients. Conclusions Improvements in HRQoL for IBD patients on anti‐ TNF therapy were sustained for longer than one year. HRQoL measures for IBD patients treated with anti‐ TNF therapy for <1 year do not differ significantly from those treated for ≥1 year, but a trend towards improved HRQoL measures with prolonged therapy can be obtained.